Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04966299
Other study ID # EryAdo
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 18, 2021
Est. completion date July 2024

Study information

Verified date March 2024
Source University Hospital, Basel, Switzerland
Contact Bettina K. Wölnerhanssen, PD. MD
Phone + 41 61 685 86 32
Email bettina.woelnerhanssen@claraspital.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Childhood and adolescence are crucial periods for prevention of obesity, as obese children are five times more likely to be obese at adulthood than lean children. To this purpose, sugar consumption should be reduced. The sugar alcohol erythritol is increasingly popular as sugar substitute in the food industry and is also recommended to diabetic patients. The substance is freely available. Recent acute studies show that erythritol has a positive influence on satiation and gastric emptying without affecting insulin and plasma glucose. In this trial, the investigators aim to assess the effect of a chronic intake of erythritol versus sucrose on insulin resistance in healthy adolescents. EryClot-Pilot: Erythritol is also produced by the human body and possibly elevated erythritol levels in the blood are an indication of an increased risk of cardiovascular disease, obesity or diabetes in the future. In a recently published study, a possible effect of erythritol on blood clotting function was described. In this in vitro experiment, increased blood clotting was observed when erythritol was added to clotting cells (platelets) in the test tube. Studies in humans on blood coagulation after administration of erythritol are missing so far. With a pilot study, the investigators study whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood coagulation function after administration of erythritol will be investigated. These preliminary tests serve to clarify the data situation so that further studies can be based on them.


Description:

This trial aims to assess the effects of the daily intake of an erythritol-sweetened beverage over 5 weeks on insulin resistance, glucose tolerance and metabolism as well as on gut microbiota. Moreover, this study will also assess the effect of the above-mentioned intervention on food intake, body composition and gastrointestinal tolerance in this population. EryClot-Pilot: The aim of this pilot study is to investigate whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood clotting function after administration of erythritol will be investigated.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 55 Years
Eligibility EryAdo: Inclusion Criteria: - Healthy adolescents - Aged 14-18 years - Normal weight (BMI between 15th and 85th percentile for age and gender) - Minimum weight of 45kg - Regular sugar consumption >25g/d Exclusion Criteria: - Severe acute or chronic diseases - Pregnancy - Regular intake of prebiotics - Regular intake of probiotics - Regular intake of pro-/prebiotic foods - Antibiotics cure within 3 months preceding the present study - Substance abuse - Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) - Participation in another study with investigational drug within the 30 days preceding and during the present study. - Pre-existing regular consumption (>1/week) of erythritol - Fructose-intolerance - Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.) EryClot-Pilot: 3 participants Inclusion criteria: - Healthy participants 18-55 years upon inclusion - Normal weight (BMI between 19.0-24.9 kg/m2) - Informed consent signed by participant Exclusion criteria: - Severe acute or chronic diseases - Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening - Substance abuse, smoking - Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) - Participation in another study with investigational drug within the 30 days preceding and during the present study. - Pre-existing regular consumption (>1/week) of erythritol - Fructose-intolerance

Study Design


Intervention

Dietary Supplement:
Eryhtritol
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks EryClot-Pilot: Erythritol 50g dissolved in 300mL water administered once per visit
Sucrose
Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
Glucose
Glucose 75g dissolved in 300mL water administered once per visit
Fructose
Fructose 25g dissolved in 300mL water administered once per visit

Locations

Country Name City State
Switzerland St. Claraspital Basel Basel-Stadt

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Insulin resistance Insulin resistance as measured by the HOMA Index. Change from baseline to 5 weeks after polyol/sucrose intake
Primary EryClot-Pilot Thrombocyte aggregation Thrombocyte aggregation after consumption of test solution measured with a blood sample Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes
Secondary Glucose tolerance: Insulin Insulin levels during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Glucose Glucose levels during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: C-Peptide C-peptide levels during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Glucagon Glucagon levels during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Fructosamin Fructosamin levels Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: HbA1C HbA1C levels Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Continuous glucose monitoring average Continuous glucose monitoring for average glucose levels Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Continuous glucose monitoring glucose variability Continuous glucose monitoring for glucose variability Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose tolerance: Continuous glucose monitoring time within range Continuous glucose monitoring for time within range Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Glucose absorption Glucose absorption measured by 3-OMG concetrations during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Metabolomics Metabolomics in plasma, urine and stool samples, measured by 1H-NMR and Liquid Chromatography-Mass Spectrometry (LC-MS). Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gut microbiota composition The taxonomic and functional profiles of the gut microbiota (stool samples) assessed by metagenomic shotgun sequencing. Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gastrointestinal hormones secretion: GLP-1 Secretion of GLP-1 during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gastrointestinal hormones secretion: PYY Secretion of PYY during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gastrointestinal hormones secretion: Ghrelin Secretion of Ghrelin during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gastrointestinal hormones secretion: CCK Secretion of CCK during OGTT Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Food intake Food intake assessed with self-reported food records Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Gastrointestinal tolerance Gastrointestinal tolerance recorded by the "Gastrointestinal Symptoms Rating Scale" (GSRS), 15 items rated on 7 Point Likert-Scale, a higher score means a worse outcome. Maximum score: 90, Minimum score: 0 Change from baseline to 3 and 5 weeks after polyol/sucrose intake
Secondary Body composition: fat mass Body composition assessed by mean of bioimpedance analysis: fat mass in kg Change from baseline to 5 weeks after polyol/sucrose intake
Secondary Body composition: fat free mass Body composition assessed by mean of bioimpedance analysis: fat free mass in kg Change from baseline to 5 weeks after polyol/sucrose intake
Secondary EryClot-Pilot Blood p-Selectin concentrations Blood p-Selectin concentrations after consumption of test solution Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes and 24, 48 hours
Secondary EryClot-Pilot Blood Erythritol concentrations Blood Erythritol concentrations after consumption of test solution Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes and 24, 48 hours
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4